VivoSeq
Other

Infusion

0

Pipeline Programs↗

20

Active Trials↗

36

Companies Involved↗

Infusion is an early-stage landscape with 0 programs across 36 companies. The most active players are Novartis, Daiichi Pharmaceuticals, Boehringer Ingelheim.

Intelligence

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

22/100

Mech. Concentration

N/A

Completion Rate

82/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalD

Daiichi Pharmaceuticals

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalL

Lee's Pharmaceutical Limited

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

182

clinical trials

Completed117 · 64%
Unknown status19 · 10%
Recruiting14 · 8%
Withdrawn13 · 7%
Terminated11 · 6%
Active, not recruiting4 · 2%
Other4 · 2%

Clinical Trials

Trial Activity

182 trials

Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients
Recruiting·IIRCCS Azienda Ospedaliero-Universitaria di Bologna·N/A·NCT06885476·22 enrolled
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
Recruiting·—·Phase 1·NCT05773326·12 enrolled
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
Recruiting·MMasonic Cancer Center, University of Minnesota·N/A·NCT01451502·250 enrolled
Serial Amnioinfusions as Regenerative Therapy for Pulmonary Hypoplasia
Recruiting·MMayo Clinic·Phase 1·NCT03723564·40 enrolled
Home Based Infusions for Ocrelizumab
Recruiting·UUniversity of Colorado, Denver·Phase 4·NCT04650321·110 enrolled
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
Recruiting·IIsala·Phase 4·NCT06031233·679 enrolled
Lumason® Infusion vs. Bolus Administrations
Recruiting·BBracco Diagnostics, Inc·Phase 3·NCT06400004·106 enrolled
Programmed Intermittent Epidural Bolus Compared With Continuous Infusion in Multiparous Women
Recruiting·HHoly Family Hospital, Nazareth, Israel·N/A·NCT06580327·186 enrolled
Iron Infusion in Patients Undergoing Transcatheter Aortic Valve Implantation
Recruiting·EErasmus Medical Center·Phase 4·NCT07370688·402 enrolled
Post Operative Infusion Pump Pain Study
Recruiting·RRutgers, The State University of New Jersey·Phase 4·NCT07349810·80 enrolled
Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 Infusion
Recruiting·—·N/A·NCT07398300·36 enrolled
Continous Infusion of Nefopam for Patients Undergoing Pancreatoduodenectomy
Recruiting·IIuliu Hatieganu University of Medicine and Pharmacy·Phase 4·NCT07423650·93 enrolled
A Trial of Three- and Seven-days Insulin Infusions Set
Recruiting·SSteno Diabetes Center Copenhagen·N/A·NCT06532461·80 enrolled
Continuous Infusions vs Scheduled Bolus Infusions
Recruiting·SStanford University·Phase 4·NCT03230565·240 enrolled
Infusion of Apomorphine: Long-term Safety Study
Active, not recruiting·Supernus Pharmaceuticals, Inc. logoSupernus Pharmaceuticals, Inc.·Phase 3·NCT02339064·99 enrolled
Page 1 of 13

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)